James Brophy, MD, PhD
Brophy J. In high-risk obese or overweight patients, lorcaserin did not increase or decrease CV events at 3.3 years. Ann Intern Med. 2018;169:JC66. doi: 10.7326/ACPJC-2018-169-12-066
Download citation file:
Published: Ann Intern Med. 2018;169(12):JC66.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use